Skip to main content

Advertisement

SpringerLink
Log in

A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Objectives

AUY922 is a novel heat shock protein inhibitor with preclinical activity in pancreatic cancer. This phase II study evaluated the efficacy of AUY922 in patients with advanced pancreatic cancer previously treated with chemotherapy.

Methods

In this single-arm, Simon two-stage phase II trial, patients with metastatic or locally advanced pancreatic ductal adenocarcinoma who had progressed on at least one line of chemotherapy and were of good performances status (ECOG 0 or 1) were treated with AUY922 at a dose of 70 mg/m2 IV weekly. The primary endpoint was disease control rate (objective response and stable disease ≥16 weeks).

Results

Twelve patients were accrued, all of whom received treatment. At least possibly related ≥grade 3 adverse events included fatigue (8 %) and AST elevation (8 %). Ten patients were evaluable for response with 1 (10 %) having stable disease and 9 (90 %) progressive disease. The median progression-free survival was 1.6 months, and the median overall survival was 2.9 months.

Conclusions

AUY922 was not associated with significant efficacy in previously treated patients with advanced pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rahib L et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921

    Article  CAS  PubMed  Google Scholar 

  2. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

    Article  CAS  PubMed  Google Scholar 

  3. Von Hoff DD et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703

    Article  Google Scholar 

  4. Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787–4792

    Article  CAS  PubMed  Google Scholar 

  5. Cantore M, Rabbi C, Fiorentini G et al (2004) Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 67:93–97

    Article  CAS  PubMed  Google Scholar 

  6. Demols A, Peeters M, Polus M et al (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94:481–485

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Xiong HQ, Varadhachary GR, Blais JC et al (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113:2046–2052

    Article  CAS  PubMed  Google Scholar 

  8. Sudo K, Yamaguchi T, Nakamura K et al (2011) Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 67:249–254

    Article  CAS  PubMed  Google Scholar 

  9. Wolpin BM, Hezel AF, Abrams T et al (2009) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27:193–198

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hosein PJ, de Lima Lopes G Jr, Pastorini VH et al (2013) A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 36(2):141–156

    Article  Google Scholar 

  11. Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26:4508

    Google Scholar 

  12. Gill S, Ko YJ, Cripps C et al (2014) PANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). J Clin Oncol 32(5s):4022

    Google Scholar 

  13. Renouf DJ et al (2014) A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Eur J Cancer (Oxf Engl 1990) 50:1909–1915

    Article  CAS  Google Scholar 

  14. Pearl LH, Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 71:271–294

    Article  Google Scholar 

  15. Pratt W, Toft D (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 228:111–133

    CAS  Google Scholar 

  16. Kamal A, Thao L, Sensintaffar J et al (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407–410

    Article  CAS  PubMed  Google Scholar 

  17. Novartis AUY922 Investigator’s Brochure, July 2010

  18. Erlichmann C (2009) Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs 18(6):861–868

    Article  Google Scholar 

  19. Jensen M, Schoepfer J, Radimerski T et al (2008) NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10(2):R33

    Article  PubMed  PubMed Central  Google Scholar 

  20. Moser C, Lang SA, Hackl C et al (2012) Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res 32(7):2551–2561

    CAS  PubMed  Google Scholar 

  21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  22. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10

    Article  CAS  PubMed  Google Scholar 

  23. Infante JR, Somer BG, Park JO et al (2014) A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 50(12):2072–2081

    Article  CAS  PubMed  Google Scholar 

  24. Ko AH, Bekaii-Saab T, Van Ziffle J et al (2016) A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma. Clin Cancer Res 22(1):61–68

    Article  CAS  PubMed  Google Scholar 

  25. Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33(3):244–250

    Article  CAS  PubMed  Google Scholar 

  26. Holter S, Borgida A, Dodd A et al (2015) Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33(28):3124–3129

    Article  CAS  PubMed  Google Scholar 

  27. Le DT, Wang-Gillam A, Picozzi V et al (2015) Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33(12):1325–1333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Phase II study of MEDI4736 monotherapy or in combinations with tremelimumab in metastatic pancreatic ductal carcinoma. NCT02558894

  29. Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Riazy M, Kalloger S, Sheffeld B et al. (2015) Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Modern Pathol 28(10): 1383–1389

    Article  CAS  Google Scholar 

  31. Waddell N et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495–501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Sausen M, Phallen J, Adleff V et al (2015) Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 7(6):7686

    Article  Google Scholar 

  33. Moffitt RA, Marayati R, Flate EL et al (2015) Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 47(10):1168–1178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bailey P, Chang DK, Nones K et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531(7592):47–52

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by a grant from Novartis. Novartis did not contribute to the data analysis, interpretation, or manuscript writing.

Author information

Authors and Affiliations

  1. British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, BC, V5Z4E6, Canada

    D. J. Renouf & M. J. Moore

  2. University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada

    D. Hedley, M. K. Krzyzanowska, M. Schmuck & L. Wang

Authors
  1. D. J. Renouf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Hedley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. K. Krzyzanowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Schmuck
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. J. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. J. Renouf.

Ethics declarations

Conflict of interest

The authors declare that they have no relevant conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Renouf, D., Hedley, D., Krzyzanowska, M.K. et al. A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer. Cancer Chemother Pharmacol 78, 541–545 (2016). https://doi.org/10.1007/s00280-016-3102-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-016-3102-y

Keywords

Search

Navigation